Navigation Links
Transcreener Assays Highlighted for Challenging Microbial, Cancer and Epigenetic Drug Targets at SLAS 2013
Date:2/6/2013

Madison, WI (PRWEB) February 06, 2013

BellBrook Lab's Transcreener HTS Assays were featured in seven posters at the SLAS 2013 Conference and Exhibition in Orlando, the week of Jan 13th. BellBrook presented four posters of their own, and there were an additional three posters by BellBrook customers, all of whom are leveraging the power of the Transcreener platform to screen enzyme targets that would be very difficult to detect in an HTS-compatible format using any other approach. Illana Stroke from Venenum BioDesign presented on the use of the Transcreener ADP Assay for screening Clostridium dificile toxins (TP148). Laura Pedro-Rosa from Scripps, Jupiter presented on her screen for a Trypansoma tRNA synthetase using the Transcreener AMP/GMP Assay (MP058). David Whalley from the MRC in London presented on a screen for PAICS, a bifunctional synthetase in the de novo purine biosynthetic pathway that is being targeted for metastatic breast cancer (TP166). These posters can be viewed in the SLAS ePoster Gallery using the indicated codes.

BellBrook's presentations included 1) a poster and a tutorial showing how their new Transzyme Methyltransferase Assay Kits simplify methyltransferase screening and profiling by combining the universal Transcreener EPIGEN Assay with pre-calibrated enzymes from Reaction Biology, 2) a poster showing that, in comparison with other ADP detection methods, the Transcreener ADP assay is more sensitive, provides greater reagent and signal stability and is more highly validated in peer reviewed publications, especially for HTS applications; 3) a study that shows – for the first time – detection of GTPase activity using full length LRRK2 (kindly provided by Life Technologies early access program); 4) a poster showing how the three major classes of human glycosyltransferases can be detected with different Transcreener assays. BellBrook posters are all available as pdfs on the company's Transcreener Posters webpage.

About BellBrook Labs. BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10396312.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
2. Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays
3. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
4. Seahorse Launches Reagent to Make Functional Fatty Acid Oxidation (FAO) Assays Easy
5. 2012 Global Factor Assays Market Outlook: Test Volume Forecasts by Country and Market Segment
6. IntelliCyt Introduces New System for Multiplexed Screening of Suspension Assays
7. Developing Robust Potency Assays for Validation, New Webinar hosted by Xtalks
8. Biomass characterization technology research highlighted in Industrial Biotechnology journal
9. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
10. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
11. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 22, 2017 , ... ... and photonics , have been named Fellows of the Society this year, the ... contributions in the multidisciplinary fields of optics, photonics, and imaging as well as ...
(Date:2/22/2017)... 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics ... biopharmaceutical products for companion animals, will host a live conference ... to discuss financial results from the fourth quarter and full ... and investors may access the audio webcast or ... ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... is has acquired Kendall Research Systems, LLC (KRS) clinical development program. ... develops neural interface technology for research and clinical applications. The terms of the ...
(Date:2/22/2017)... Clara, CA (PRWEB) , ... February 22, 2017 , ... ... hosting a free AFM Luncheon for all SPIE attendees and ... Jose, CA, just one block from the San Jose Convention Center. The luncheon ...
Breaking Biology Technology:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
Breaking Biology News(10 mins):